Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 3,665 matching trials from the live ClinicalTrials.gov search.
Conditions
Lung Cancer
Interventions
cytology specimen collection procedure, physiologic testing, annual screening, study of high risk factors
Other · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years and older
Enrollment
3,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1994
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Multiple Myeloma
Interventions
Oral microbiota assessment, Comprehensive chemical gustometry, Measurement of salivary flow, Surveys assessing taste disturbances
Diagnostic Test · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Pulmonary Arterial Hypertension
Interventions
Measurement of oxyhemoglobin and deoxyhemoglobin concentration pre and post- exercise at baseline and Week 12. Measurement of time to recovery of oxyhemglobin post-exercise at baseline and at Week 12., Blood draw
Device · Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Kidney Transplant Rejection
Interventions
Diagnostic Test: TruGraf® Testing
Diagnostic Test
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
La Jolla, California
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions
Biospecimen Collection, Educational Intervention, Extended Release Metformin Hydrochloride, Questionnaire Administration
Procedure · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Duarte, California • La Jolla, California • Riverside, California
Conditions
Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers
Interventions
Humanized 3F8 Bispecific Antibody, Blood draw
Biological · Other
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
1 Year to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

VIDAS® NEPHROCLEAR Reference Interval Study

NCT06037109
Conditions
Healthy
Interventions
Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test
Device
Lead sponsor
BioMérieux
Industry
Eligibility
21 Years and older
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Chicago, Illinois
Conditions
Liver Cancer
Interventions
biologic sample preservation procedure, medical chart review, Patient interview
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Conditions
Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
17
States / cities
Encinitas, California • Irvine, California • La Jolla, California + 12 more
Conditions
Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Low Dose Computed Tomography of the Whole Body, Magnetic Resonance Imaging, Positron Emission Tomography, Venetoclax, X-Ray Imaging, Questionnaire Administration
Procedure · Biological · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Malignant Uterine Neoplasm, Uterine Corpus Carcinosarcoma
Interventions
Biospecimen Collection, Liquid Biopsy, Pap Smear
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer, Cancer of the Breast
Interventions
VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay, Anastrozole, Combination anthracycline and/or taxane based treatment
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
COVID-19, Influenza A, Influenza Type B
Interventions
Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
14 Years to 100 Years
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Easley, South Carolina
Terminated Not applicable Interventional Results available

Evaluation of a Disposable Flexible Bronchoscope, aScope IV

NCT02255838
Conditions
Respiratory Insufficiency, Pneumonia, Atelectasis
Interventions
Bronchoscope reusable (Storz 8402 2x), Bronchoscope disposable (aScope 4)
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Azithromycin in Control of Trachoma II

NCT00286026
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Detection of Early Idiopathic Pulmonary Fibrosis

NCT03457935
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
blood samples
Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Larotrectinib Sulfate, Magnetic Resonance Imaging, Radionuclide Imaging, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
122
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Acupressure Therapy, Best Practice, Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm
Interventions
Axatilimab, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Survey Administration
Biological · Drug · Procedure + 1 more
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Stage, Colon Cancer, Stage I-III Colon Cancer, Stage IV Colon Cancer With Resectable Liver Metastases
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Differential Risks for Melanoma: p16 and DNA Repair

NCT00615095
Conditions
Melanoma, Skin Melanoma
Interventions
self-administered questionnaire and blood draw, health questionnaire, blood draw and skin exam
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection, Bone Marrow Biopsy, Busulfan, Fludarabine
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Cervical Carcinoma
Interventions
HPV Self-Collection, Informational Intervention, Interview, Survey Administration, Receive screening results, Receive recommended steps following abnormal results, Telephone-Based Intervention
Procedure · Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Cancer, Breast Benign
Interventions
Breast MRI, Breast Mammogram, Blood draw, Breast Biopsy, online participant reported questionnaire
Device · Other · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
7
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 4 more